Antiretroviral therapy in children with tuberculosis: Progress toward defining the issues
dc.contributor.author | Cotton M.F. | |
dc.contributor.author | Rabie H. | |
dc.contributor.author | Van Zyl G.U. | |
dc.date.accessioned | 2011-05-15T16:03:32Z | |
dc.date.available | 2011-05-15T16:03:32Z | |
dc.date.issued | 2010 | |
dc.description.abstract | [No abstract available] | |
dc.description.version | Note | |
dc.identifier.citation | Journal of Infectious Diseases | |
dc.identifier.citation | 201 | |
dc.identifier.citation | 8 | |
dc.identifier.issn | 221899 | |
dc.identifier.other | 10.1086/651455 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/12669 | |
dc.subject | anti human immunodeficiency virus agent | |
dc.subject | cytochrome P450 | |
dc.subject | efavirenz | |
dc.subject | lopinavir plus ritonavir | |
dc.subject | nelfinavir | |
dc.subject | nevirapine | |
dc.subject | rifampicin | |
dc.subject | ritonavir | |
dc.subject | tuberculostatic agent | |
dc.subject | virus RNA | |
dc.subject | Africa | |
dc.subject | bacterium culture | |
dc.subject | CD4 lymphocyte count | |
dc.subject | cohort analysis | |
dc.subject | drug exposure | |
dc.subject | drug hypersensitivity | |
dc.subject | drug megadose | |
dc.subject | enzyme activity | |
dc.subject | failure to thrive | |
dc.subject | highly active antiretroviral therapy | |
dc.subject | human | |
dc.subject | Human immunodeficiency virus | |
dc.subject | Human immunodeficiency virus infected patient | |
dc.subject | Human immunodeficiency virus infection | |
dc.subject | mixed infection | |
dc.subject | note | |
dc.subject | palatability | |
dc.subject | patient compliance | |
dc.subject | priority journal | |
dc.subject | single drug dose | |
dc.subject | South Africa | |
dc.subject | thorax radiography | |
dc.subject | treatment failure | |
dc.subject | treatment outcome | |
dc.subject | tuberculosis | |
dc.subject | vertical transmission | |
dc.subject | virus load | |
dc.subject | Anti-HIV Agents | |
dc.subject | Antiretroviral Therapy, Highly Active | |
dc.subject | Antitubercular Agents | |
dc.subject | Child | |
dc.subject | Child, Preschool | |
dc.subject | HIV Infections | |
dc.subject | Humans | |
dc.subject | Infant | |
dc.subject | Ritonavir | |
dc.subject | Tuberculosis, Pulmonary | |
dc.title | Antiretroviral therapy in children with tuberculosis: Progress toward defining the issues | |
dc.type | Note |